Introduction {#s1}
============

Infertility is a significant problem in society, affecting 15% of reproductive-aged couples ([@DER391C25]; [@DER391C34]; [@DER391C38]). Many cases of infertility appear to be the result of defects in germ cell development that lead to reduced numbers or quality of gametes. The quantity and quality of oocytes within the ovaries, or ovarian reserve, are closely correlated with reproductive potential and are likely to have multiple genetic and environmental determinants. Further, ovarian reserve is affected by aging and disease, and is closely tied to both reproductive and somatic health. Many diseases including osteoporosis, cardiovascular disease and various cancers are associated with loss of oocytes/follicles, ovarian dysfunction and/or the length of the female reproductive lifespan ([@DER391C8]; [@DER391C23]). Hence, better prediction of both normal and aberrant oocyte depletion would have significant clinical implications.

Several reproductive hormones are closely correlated with the ovarian reserve and the inevitable process of follicle depletion. Current methods for measuring ovarian reserve and predicting age at fertility loss and menopause include assessment of serum levels of FSH, inhibin B and anti-Mullerian hormone (AMH), which decreases ∼10 years prior to menopause ([@DER391C47]). AMH and FSH are direct and indirect reflections of follicle number, respectively. AMH is a member of the transforming growth factor-β superfamily; it suppresses the cyclical recruitment of primordial follicles into the pool of growing follicles and is specifically secreted by the granulosa cells of pre-antral and antral follicles in the ovary ([@DER391C14]). Thus, AMH is present in proportion to the number of antral follicles. FSH on the other hand, is an indirect reflection of the follicle pool; it is a gonadotrophin secreted by the anterior pituitary in response to hypothalamic release of GnRH. It stimulates follicular growth and is a key component of the brain-pituitary-ovary axis ([@DER391C20]). FSH is sensitive to the inhibitory influence of inhibin B. Inhibin B is secreted by the granulosa cells of developing and early antral follicles. So as the number of follicles declines, so do inhibin levels and FSH begins to rise. Thus, there is an association between high FSH and low follicle number with ovarian aging.

Antral follicle count (AFC), transvaginal ultrasound-guided assessment of follicles, is routinely performed during fertility assessments. We have recently analyzed the correlations of several hormonal markers and AFC with age in Caucasian women (unpublished data), finding that only AFC and AMH parallel the decline of follicles with age noted in histological ovarian specimens ([@DER391C21]). In contrast, FSH shows an inverse relationship with AFC and follicle number *in vivo*; as follicle number and AMH decline, FSH rises. It is noteworthy that both AMH and FSH levels are highly variable among women, even measured at the same point in the menstrual cycle.

The age of menopause has a strong heritability ([@DER391C41]; [@DER391C12]; [@DER391C35]). Ovarian aging (OVA), which leads to menopause with the exhaustion of the follicular pool, also seems to have a genetic component ([@DER391C39]). Genetic markers associated with ovarian reserve may have the advantage of providing better long-range predictions of risk for declining ovarian reserve. Thus, determining the genetic associations of rising FSH and declining AMH may allow for improved counseling regarding reproductive health and aging.

Most previous work has focused on measuring the reproductive events of menarche and menopause, or comparing ovarian reserve markers and their ability to predict reproductive outcomes in the context of infertile populations or small observational studies. Moreover, few studies have investigated the genes or variants associated with specific reproductive hormones. Therefore, we sought to identify genes and variants across the genome associated with hormonal markers of ovarian reserve in a multi-ethnic cohort recruited from the general population. We also sought to examine the effects of environmental or lifestyle factors including smoking and oral contraceptive use, on ovarian reserve phenotypes.

Materials and Methods {#s2}
=====================

Study population {#s2a}
----------------

The final study population included 232 Caucasian and 200 African American women, aged 25--45 years, who were prospectively enrolled in a community-based cohort of the OVA Study. These women were not seeking treatment for infertility or other medical problems. The OVA Study comprises a multi-ethnic cohort and is focused on elucidating clinical and genetic markers of OVA. Subjects were recruited from potentially eligible female members of Kaiser Permanente (KP) Northern California, who resided within proximity to the Women\'s Health Clinical Research Center at the University of California San Francisco (UCSF). The socio-demographic and health-related characteristics of the KP patient population are representative of the population of Northern California ([@DER391C19]), and the final OVA participants were similar to the KP population. Subjects were included if they were ovulatory with normal predictable menstrual cycles of 22--35 days. Women with oligo- or anovulation, surgically diagnosed endometriosis, ovarian failure (loss of all follicles before the age of 40 years) or a history of uterine or ovarian surgery were excluded. Subjects were also excluded if they had taken oral contraceptives or medications containing estrogen or progestin that alter the menstrual cycle within the 3 months prior to enrollment. This work was approved by the Institutional Review Boards at KP, UCSF and Stanford University, and informed consent was obtained for all subjects.

Phenotypes and covariates of ovarian reserve {#s2b}
--------------------------------------------

Blood samples were collected by venipuncture on Day 2--4 of the menstrual cycle and used for all serum hormonal assays and genotyping. FSH and LH levels were measured with standardized two-site chemiluminescence immunoassays. The intra-assay coefficients of variation (CVs) were 1.9--2.1%, whereas the inter-assay CVs were 5.2--6.8%. AMH was measured using a commercially available ELISA, which uses a direct competitive immunoassay (Beckman Coulter, Marsee, France). The AMH CVs for intra- and inter-assays were \<5.6 and \<15.3%, respectively. Estrone (E~1~) and inhibin B were measured using a commercially available ELISA (Diagnostic Systems Laboratories, Webster City, TX, USA). The intra-assay CVs for E~1~ and inhibin B were 4.8--9.9 and 3.3--7.2%, respectively, whereas the inter-assay CVs were 7.7--13.4 and 7.8--17%, respectively. Estradiol (E~2~) and testosterone were measured with an automated chemiluminescent assay using the Bayer Diagnostics ACS:180 (Bayer Diagnostics Corp., Tarrytown, NY, USA). The intra- and inter-assay CVs for E~2~ were 6.5--6.9 and 13.6--16.1%, respectively. For total testosterone, the intra-assay CVs were 2.9--4.0% and the inter-assay CVs were 6.3--6.6%.

AFCs were performed as previously described ([@DER391C40]). Briefly, all subjects underwent transvaginal ultrasound assessment of ovarian volumes and AFC on Day 2--4 of their menstrual cycle. All follicles with a mean diameter (of two dimensions) of 2--10 mm were counted; all echo-free structures were regarded as follicles ([Supplementary data, Fig. S1](http://humrep.oxfordjournals.org/lookup/suppl/doi:10.1093/humrep/der391/-/DC1)). To eliminate experimental variability all women were examined at the same time in their menstrual cycle, by one of two physicians, using the same equipment, and unclear ultrasound results were excluded. Inter-examiner concordance exceeds 90%.

All subjects completed a comprehensive questionnaire to obtain detailed health, reproductive, lifestyle and demographic information, as previously described ([@DER391C40]). The age of each woman was rounded off to the nearest 10th of a year. Body measurements including weight, height and waist and hip circumference, were also obtained. Parity or the number of children born to each woman was also assessed. Cigarette smoke exposure was quantified from responses to questionnaire data and categorized as 'never, past or current' smoker and pack-years of smoking. Previous history of taking estrogen- and/or progestin-containing oral contraceptive pills (OCPs) was also quantified from questionnaire data and categorized as 'never or past' and total months of OCP use.

Genotyping and quality control {#s2c}
------------------------------

Genotypic data for the Caucasian and African American women was obtained using the Genome-Wide Human SNP Array 6.0 (Affymetrix, Santa Clara, CA, USA). This microarray contains more than 900 000 single nucleotide polymorphism (SNP) markers and 940 000 copy number variant (CNV) markers; approximately one marker every 700 bases across the genome ([@DER391C1]). Genomic DNA was extracted and purified from white blood cells using the QIAamp DNA Blood Maxi Kit (Qiagen, Venlo, The Netherlands) according to the manufacturer\'s instructions. The DNA ligation, hybridization and microarray scanning steps were completed according to the manufacturer\'s protocols (Affymetrix).

Stringent quality control (QC), concordance checks and SNP filtering were employed using Genotyping Console (GTC) v.4.0 software (<http://www.affymetrix.com>) to eliminate poor samples and poorly performing or rare SNPs. The QC measures used were: QC call rate or percentage of a specific set of 3022 control SNPs genotyped or 'called' in the samples using the dynamic algorithm (filtered for QC call rate ≥86%); and contrast QC, which is an estimate of the ability to resolve SNP signals into three genotype clusters (filtered for contrast QC ≥0.4). Contrast QC, the most important QC measure, uses a static set of 10 000 randomly chosen SNPs and quantifies the difference between the highest and lowest contrast values of the homozygote and heterozygote genotypes. Laboratory technical QC criteria also included SNP fingerprints for sample tracking and early detection of sample misidentification, the use of HapMap controls to check genotype quality, gender confirmation based on mean intensities of SNP probes on the X and Y chromosomes, and tracking of reagent and instrument performance. In the Caucasian group, of the final 232 samples that passed QC and filter criteria, the mean contrast QC was 1.87 ± 0.046, the QC call rate was 93.9 ± 0.2% and the overall sample call rate was 98.0 ± 0.08%. In the African American group, of the final 200 samples, the mean contrast QC was 2.23 ± 0.036, the QC call rate was 97.0 ± 0.1% and the overall sample call rate was 99.4 ± 0.08%. SNPs were genotyped using GTC v.4.0, using the Birdseed v.2.0 algorithm ([@DER391C31]), which is an extension of the Bayesian Robust Linear Model with Mahalanobis Distance using perfect-match probes. Clustering analysis and examination of relative sample intensity, as well as filtering for high sample call rates (≥95%) ensured high sample quality prior to downstream association analysis. Individual SNPs across the genome were filtered for SNP call rates \>95%, missing call rates \<5%, minor allele frequency (MAF) \>1% and lack of significant deviation from Hardy--Weinberg equilibrium (*P*\> 0.007). Of 909 622 SNP probes on the array, 677 261 and 738 185 in the Caucasian and African American cohorts, respectively, passed QC and SNP filter criteria and were independently tested for association with FSH and AMH. Using the 940 000 CNV probes on the array, future investigations will examine CNVs across the genome and their association with hormonal and clinical markers of ovarian reserve. All SNP locations are referenced to National Center for Biotechnology Information (NCBI) human genome build 37 (February 2009) and dbSNP build 131 (April 2010) (<http://www.ncbi.nlm.nih.gov/projects/SNP>). Gene names provided in all tables and text represent the HUGO Gene Nomenclature Committee (HGNC) gene symbols of the gene containing, or closest to, the identified SNP (<http://www.genenames.org>[/](/)).

Determination of population structure {#s2d}
-------------------------------------

For ethnicity validation and tests of population structure a principal component analysis (PCA) using singular value decomposition (svd) was performed. Subjects of the HapMap CEU (Utah residents with N. and W. European ancestry from the CEPH collection) and YRI (Yoruban in Ibadan, Nigeria) cohorts were genotyped using the same genotyping platform (<http://hapmap.ncbi.nlm.nih.gov/>) ([@DER391C26]). The OVA cohorts were combined with the HapMap CEU and YRI cohorts, and missing genotypes were imputed using the program BEAGLE v.3.0.2 (<http://www.stat.aukland.ac.nz/~bbrowning/beagle/beagle>) ([@DER391C6]; [@DER391C7]). Genotypes at 10 000 SNPs, selected to have low levels of linkage disequilibrium (LD) and MAF \>0.01, distributed across several chromosomes were coded as 0, 1 or 2 (AA, AB and BB) and were mean-centered. PCA was performed using the 'svd' function of the statistical program R v.2.11.1 (<http://www.r-project.org/>) ([@DER391C17]) to analyze allele composition and population homogeneity ([Supplementary data, Fig. S2](http://humrep.oxfordjournals.org/lookup/suppl/doi:10.1093/humrep/der391/-/DC1)).

Statistical analysis {#s2e}
--------------------

### Phenotypic and covariate analysis {#s2e1}

Descriptive statistics were calculated for all hormonal, environmental and demographic variables in the study cohorts. The relationship between hormonal variables, follicle number and age was analyzed in linear regression analyses. For binary variables including smoking and OCP use, linear regressions of the hormone concentration versus age were compared between women that currently or previously smoked or used OCPs, and those that did not. Statistical differences between the slopes and intercepts of the regressions were analyzed using the *F*-test for variable inclusion with subject age mean-centered. *P*\<0.05 was considered statistically significant. Three models with different effects of smoking (or OCP use) were tested against the simple null model of an association between the hormone alone (hormone ∼ Age). The three models tested were: (1) smoking changes the intercept (hormone ∼ Age + Smoking); (2) the slope (hormone ∼ Age + Smoking × Age) or (3) both slope and intercept (hormone ∼ Age + Smoking + Smoking × Age). For these analyses, women that previously smoked were grouped with smoking women, as we reasoned if a woman ever smoked, there may have been irreversible effects on her ovarian reserve. Similar analyses were performed on the associations between follicle number and smoking or OCP use. Pack-years of smoking and total months of OCP use were also analyzed for their association with serum hormone levels, with control for age. Outliers were removed based on sensitivity analyses. Mean total serum hormone levels or AFCs were also compared between smoking (or OCP-using) and non-smoking (or non-OCP-using) women, using the Student\'s *t*-test or Welch 2-Sample *t*-test within R v.2.11.1 ([@DER391C17]). Covariates, including smoking, OCP use and follicle number, that were significantly associated with FSH or AMH were also controlled for in downstream genome-wide association (GWA) analyses.

### SNP association analysis {#s2e2}

GWA analyses were performed in the context of a robust regression of FSH or AMH versus age using the application quantreg v.4.44 ([@DER391C30]) within R.A. Fisher\'s exact test for single-marker (SNP) and multiple-marker (haplotype) association using the allelic test was performed to determine associations with serum hormone levels using BEAGLE v.3.0.2 and quantreg v.4.44; both programs were integrated in R v.2.11.1. The effect sizes or the difference in the mean hormone level from the overall regression fit, by allele or genotype were calculated for all SNPs. In parallel validation analyses, allelic and genotypic tests using the Kruskal--Wallace rank-sum test determined SNPs significantly associated with FSH or AMH, as quantitative variables. For each SNP allele and genotype, a linear regression fit of FSH or AMH versus age was obtained, the residual was computed for each woman, and the women were ranked into groups based on the allele/genotype to determine whether one allele/genotype had higher or lower residuals (effect sizes) than expected by random chance alone. Associations determined by the Fisher\'s exact test were also significant as determined by the Kruskal--Wallace test, for all top hits.

LD of variants, the number of SNPs involved in the association signals, the genes and the recombination rates of the regions surrounding the top hits were analyzed within BEAGLE, Haploview v.4.2 (<http://www.broadinstitute.org/mpg/haploview>) ([@DER391C3]) and LocusZoom v.1.1 (<http://csg.sph.umich.edu/locuszoom/>) ([@DER391C37]). LD tagging was performed with the Tagger program ([@DER391C11]) within Haploview to capture SNPs with squared correlation coefficients of *R*^2^ ≥ 0.8 and LD of flanking SNPs was similarly analyzed within LocusZoom.

To verify associations and determine final significance levels, permutation testing (1000 tests) was performed and *P* \< 0.05 were selected for at the chromosome-wide level. Bonferonni correction for multiple testing and family-wise errors rates were computed to verify significant associations at the genome-wide level. *P*-values were computed and analyzed at both the chromosome- and genome-wide-levels, owing to our sample size/power constraints. Further, as several chromosomes have loci associated with ovarian reserve and function, variants were also analyzed specifically at the chromosome level. Although accepted genome-wide significance thresholds are typically ∼5 × 10^−8^, because of our marginal sample size (which is large for a clinical/biological study but moderate for a GWA study), assuming a slightly higher genome-wide threshold of *P*\< 1 × 10^−7^, we note that the top hit identified in this study is at a marginal genome-wide significance level. Custom-made programs and algorithms were used to mediate streamlined analyses and visualization of results within R.

Results {#s3}
=======

Genetic association analysis {#s3a}
----------------------------

As shown in Table [I](#DER391TB1){ref-type="table"}, in 232 Caucasian and 200 African American women, the average FSH levels were 7.1 ± 0.2 and 7.4 ± 0.3 IU/l, respectively. The mean AMH level was 30.1 ± 1.5 pM in Caucasians and 22.8 ± 1.7 pM in African Americans, with a significant difference between the two racial groups (*P*\< 0.001). Both hormones were correlated with female age (Fig. [1](#DER391F1){ref-type="fig"}) and follicle number (*P*\< 0.05). In Caucasian women, FSH had an extrapolated rate of increase of ∼0.27 IU/l per year of female age (Fig. [1](#DER391F1){ref-type="fig"}A). In African American women, similar relationships were observed, with a rise of ∼0.16 IU/l of FSH per year of female age (Fig. [1](#DER391F1){ref-type="fig"}A). AMH was most closely correlated with both female age (Caucasians: *R*^2^ = 0.22; African Americans: *R*^2^ = 0.043) and follicle number (Caucasians: *R*^2^ = 0.67; African Americans: *R*^2^ = 0.36; *P*\< 0.05); AMH decreased with increasing age and declining AFCs. In Caucasian women, AMH decreased ∼2 pM per year, while in African American women it decreased ∼0.84 pM per year (Fig. [1](#DER391F1){ref-type="fig"}B). Both FSH and AMH levels were less strongly correlated with age in the African American population, compared with the Caucasian population (FSH: *R*^2^ = 0.06 versus 0.15; AMH: *R*^2^ = 0.04 versus 0.22, respectively). FSH and AMH levels were more variable among African American women and higher follicle numbers were not always predictive of higher AMH levels. Table IVariables of the study population. CaucasiansAfrican AmericansMean ± SEM*n*Mean ± SEM*n*Age (years)35.3 ± 0.323235.6 ± 0.4200FSH (IU/l)7.1 ± 0.22327.4 ± 0.3200AMH (pM)30.1 ± 1.5\*23222.8 ± 1.7\*200LH (IU/l)5.8 ± 0.2\*2324.5 ± 0.2\*200Inhibin B (pg/ml)54.9 ± 1.9\*23244.4 ± 2.4\*200Estradiol (pg/ml)48.3 ± 3.623245.7 ± 1.7200Estrone (pg/ml)61.7 ± 1.623263.3 ± 1.6200Total testosterone (ng/dl)52.9 ± 1.0\*23245.3 ± 1.0\*200Past/current smokers^a^45.5% (15.9 ± 1.0)10623.3% (14.3 ± 1.4)47Non-smokers^a^54.5% (14.9 ± 0.7)12776.6% (16.0 ± 0.9)154OCP users^a^79% (14.9 ± 0.6)19572% (14.3 ± 0.8)145Non-OCP users^a^21% (17.2 ± 1.3)4828% (18.9 ± 1.6)56[^1][^2][^3][^4] Figure 1Measurements of FSH and AMH versus age in women of the entire study population. Total serum concentrations of FSH and female age in Caucasian and African American women indicate that FSH increases with age in both ethnic groups (**A**). Total serum concentrations of AMH versus age indicate that AMH decreases with age but is highly variable between women and is more variable among African American women (**B**). The corresponding correlation coefficients (*R*^2^) and linear equations are shown (*n* = 200--232 women).

As two good hormonal markers of ovarian reserve, FSH and AMH were independently analyzed for associations across the genome. Figure [2](#DER391F2){ref-type="fig"} shows the GWA results for FSH in African American (Fig. [2](#DER391F2){ref-type="fig"}A and B) and Caucasian (Fig. [2](#DER391F2){ref-type="fig"}C and D) women. Figure [3](#DER391F3){ref-type="fig"} depicts the genome-wide results for AMH. In the African American cohort, the top three genetic loci associated with FSH levels localized to chromosomes 2 and 10 (Fig. [2](#DER391F2){ref-type="fig"}B and Table [II](#DER391TB2){ref-type="table"}). Notably, one marginally genome-wide significant SNP (rs6543833) was associated with FSH in the African American population (*P*= 8.07 × 10^−8^). This variant, at 2p22.3, is located just upstream of the *myeloid-associated differentiation marker-like* (*MYADML*) gene and was associated with a mean increase of 1.0 ± 0.2 IU/l and a decrease of 0.6 ± 0.3 IU/l FSH for the CC and GG genotypes, respectively (MAF = 0.27; Table [II](#DER391TB2){ref-type="table"} and Fig. [4](#DER391F4){ref-type="fig"}A). The next most significant SNP, rs12465811, at the same loci on chromosome 2, was also associated with FSH (*P* = 4.28 × 10^−7^; MAF = 0.32). This variant was associated with an increase of 1.0 ± 0.2 IU/l and a decrease of 0.4 ± 0.2 IU/l FSH for the GG and TT genotypes, respectively (Table [II](#DER391TB2){ref-type="table"} and Fig. [4](#DER391F4){ref-type="fig"}A). Regional association analyses of the 800 kb surrounding these loci indicated that these variants were in LD and several nearby SNPs were involved in the association signal (Fig. [2](#DER391F2){ref-type="fig"}E). The third nominally associated variant rs11255291, localized to 10p14, upstream of the *inter-alpha (globulin) inhibitor H2* (*ITIH2*) gene and was associated with a decrease of 1.3 ± 0.2 IU/l and an increase of 1.2 ± 0.4 IU/l FSH for the TT and CC genotypes, respectively (Table [II](#DER391TB2){ref-type="table"}). Table IIVariants associated with FSH levels.SNPChrGenePositionCytobandAlleles^a^MAFAA effect^b^AB effect^b^BB effect^b^*P*-value^c^Corrected *P*-value^d^*African Americans*rs65438332*MYADML*34631032P22.3G/C0.27−0.62 ± 0.340.46 ± 0.170.96 ± 0.218.07 × 10^−8^*0.0070 (0.059)*rs124658112*MYADML*34623796P22.3T/G0.32−0.38 ± 0.240.58 ± 0.180.92 ± 0.204.28 × 10^−7^0.030 (0.32)rs1125529110*ITIH2*7736904P14T/C0.25−1.34 ± 0.220.17 ± 0.401.21 ± 0.381.53 × 10^−6^0.059 (1)*Caucasians*rs648861912*GRIN2B*13927896P13.1C/T0.25−1.10 ± 0.350.15 ± 0.241.16 ± 0.339.43 × 10^−7^0.034 (0.65)rs100618045*NPR3*32748637P13.3T/C0.282.05 ± 0.801.08 ± 0.440.091 ± 0.231.47 × 10^−6^0.052 (1)[^5][^6][^7][^8][^9] Figure 2Summary of GWA results for FSH by chromosome showing Manhattan plots of the uncorrected (**A** and **C**) and corrected (**B**  and **D**) *P*-values of the Fisher\'s exact test in the African American (A and B) and Caucasian (C and D) populations. Each point represents a SNP from the single SNPs and haplotype tests of association remaining after QC and SNP filtering (677 261 in the Caucasian cohort and 738 185 in the African American cohort). The red dashed lines indicate *P*-values of 1.5 × 10^−6^ (uncorrected) and 0.05 (corrected), chromosome-wide significance level. (**E**) Regional association analyses of 800kb (272 SNPs) flanking the top variant associated with FSH in the African American cohort (rs6543833), including the number of SNPs involved in the signal, their *P*-values, the LD among these variants, genes in the region and the recombination rates (hg build 18, HapMap Phase II CEU reference, legend showing LD). Figure 3Summary of GWA results for AMH by chromosome showing Manhattan plots of the uncorrected (**A**  and **C**) and corrected (**B**  and **D**) *P*-values of the Fisher\'s exact test in the African American (A and B) and Caucasian (C and D) populations. Each point represents a SNP from the single SNPs and haplotype tests of association remaining after QC and SNP filtering (677 261 in the Caucasian cohort and 738 185 in the African American cohort). The red dashed lines indicate *P*-values of 1.5 × 10^−6^ (uncorrected) and 0.05 (corrected), chromosome-wide significance level. Figure 4Phenotypes and genotypes of SNPs associated with FSH and AMH. Shown are scatter plots depicting high (H) and low (L) FSH and AMH by age in African American (**A**) and Caucasian (**B**) women. Shown is the distribution of genotypes among the women with respect to age and FSH or AMH for the most significant variants: (a) rs6543833 and (b) rs12465811 (for FSH) and (c) rs12213875 (for AMH). The three genotypes are designated by blue, orange and red points (*n* = 200--232 women).

In the Caucasian cohort, the top three genetic loci associated with FSH localized to chromosomes 12, 5 and 11 (Fig. [2](#DER391F2){ref-type="fig"}C and D). As summarized in Table [II](#DER391TB2){ref-type="table"}, the two most significant SNPs in the Caucasian women, rs6488619 and rs10061804, were nominally associated with FSH (*P* = 9.43 × 10^−7^ and 1.47 × 10^−6^; MAFs = 0.25 and 0.28) and localized to 12p13.1 and 5p13.3, respectively. Variant rs6488619, is located within an intron of the *glutamate receptor, ionotropic, N-methyl D-aspartate 2B* (*GRIN2B*) gene and led to a mean decrease of 1.1 ± 0.4 IU/l and an increase of 1.2 ± 0.3 IU/l FSH for the CC and TT genotypes, respectively. Analysis of the surrounding region indicated that several variants at this loci were associated with FSH and a few of these were in LD ([Supplementary data, Fig. S3A](http://humrep.oxfordjournals.org/lookup/suppl/doi:10.1093/humrep/der391/-/DC1)). Variant rs10061804 on chromosome 5 is located within an intron of the *natriuretic peptide receptor C/guanylate cyclase C* (*NPR3*) gene and was associated with increases of 2.1 ± 0.8 and 1.1 ± 0.4 IU/l FSH for the TT and CT genotypes, respectively. There were several SNPs in close proximity at the 5p13.3 region that approached chromosome-level significance (see Fig. [2](#DER391F2){ref-type="fig"}B). The last SNP, rs4944804 at 11q13.4, weakly associated with FSH, is located immediately upstream of the *ATG autophagy related 16-like 2* (*Saccharomyces cerevisiae*) (*ATG16*) gene and was associated with an increase of 1.2 ± 0.4 IU/l FSH for the GG genotype.

There were fewer genetic variants associated with AMH compared with FSH, in both Caucasian and African American women. In the African American cohort, weakly associated variants localized to 3p25.1 and 11p15.1 near or within the *tetra-peptide repeat homeobox-like* (*TPRXL*) and *transmembrane protein 86A* (*TMEM86A*) genes, respectively (Table [III](#DER391TB3){ref-type="table"} and Fig. [3](#DER391F3){ref-type="fig"}A and B). The top genetic loci in the Caucasian cohort were located on chromosome 6, with only very weakly associated variants on chromosomes 18, 4 and 13 (Fig. [3](#DER391F3){ref-type="fig"}C and D). The most significant SNP rs12213875, which was nominally associated with AMH (*P* = 2.96 × 10^−7^; MAF = 0.37) localized to 6p23 and is upstream of the *Jumonji, AT rich interactive domain 2* (*JARID2*) gene. This variant was associated with a mean increase of 13.8 ± 4.2 pM, an increase of 9.9 ± 2.1 pM and a decrease of 1.3 ± 1.4 pM AMH for the AA, AG and GG genotypes, respectively (Table [III](#DER391TB3){ref-type="table"} and Fig. [4](#DER391F4){ref-type="fig"}B). Several variants adjacent to the top SNP associated with AMH in both ethnic groups showed some degree of LD and many variants in these regions were associated with the signals ([Supplementary data, Fig. S4](http://humrep.oxfordjournals.org/lookup/suppl/doi:10.1093/humrep/der391/-/DC1)). Many other SNPs were only weakly associated with AMH levels and are located within or near the *thioredoxin-related transmembrane protein 3* (*TMX3*), *inositol polyphosphate-4-phosphatase, type II* (*INPP4B*) and *WAS protein family, member 3* (*WASF3*) genes. Interestingly, several variants associated with FSH or AMH (this study), or AFC (previous unpublished work), localized to the same genomic regions of 12p13.1--13.2 and 13q12.13. Table IIIVariants associated with AMH levels.SNPChrGenePositionCytobandAlleles^a^MAFAA effect^b^AB effect^b^BB effect^b^*P*-value^c^Corrected *P*-value^d^*African Americans*rs98755893*TPRXL*13961157P25.1A/C0.46−4.17 ± 1.824.96 ± 2.3514.02 ± 3.723.70 × 10^−6^0.15 (1)rs1229540311*TMEM86A*18689653P15.1T/G0.1045.99 ± 0.0016.67 ± 5.112.98 ± 1.685.07 × 10^−6^0.17 (1)*Caucasians*rs122138756*JARID2*14694982P23A/G0.3713.82 ± 4.189.91 ± 2.07−1.25 ± 1.412.96 × 10^−7^0.011 (0.20)rs93965036*JARID2*14644068P23T/G0.3714.92 ± 4.608.26 ± 1.97−0.07 ± 1.50 04.28 × 10^−6^0.16 (1)[^10][^11][^12][^13][^14]

In replication studies, the top variants associated with FSH were examined in the Caucasian population as an independent replication cohort. The top SNP rs6543833, had a *P*-value of 0.012 with an MAF of 0.32, while the next most significant SNP rs12465811, had a *P*-value of 0.071 with an MAF of 0.33 ([Supplementary data, Table S1](http://humrep.oxfordjournals.org/lookup/suppl/doi:10.1093/humrep/der391/-/DC1)). When only controlling for these two tests, the top SNP was significant in the replication cohort at a *P*\< 0.05 level. As shown in [Supplementary data, Table S1,](http://humrep.oxfordjournals.org/lookup/suppl/doi:10.1093/humrep/der391/-/DC1) the 300 SNPs flanking this variant were also examined and it was discovered that nine adjacent SNPs had relatively low *P*-values of 1.5 × 10^−3^ to 7.2 × 10^−3^. The regional plots of these variants and their association signals are also indicated in [Supplementary data, Fig. S3B](http://humrep.oxfordjournals.org/lookup/suppl/doi:10.1093/humrep/der391/-/DC1). Comparing the expected versus the observed numbers of SNPs in this region with these low *P*-values indicates that this cluster of SNPs was unlikely the result of random chance. There were three times as many SNPs with low *P*-values than expected based on observed *P*-value distributions. These findings provide confirmation of the top SNP as well as other associated loci in the surrounding region. Interestingly, all of these variants occurred within or upstream of the *MYADML* gene, which may represent an excellent candidate gene for future studies in women of both European and African ancestry. Replication of these findings in independent cohorts of reproductive-aged women and meta-analyses in larger combined GWA studies are needed.

In an attempt to further examine the genetic variants associated with FSH and AMH, we tested the top hits for association with another well-known marker of ovarian reserve---AFC. A total of four and five SNPs associated with FSH or AMH levels in Caucasian or African American women, respectively, were tested for association with AFC. Final *P*-values were corrected for the number of tests and considered significant at a level of *P*\< 0.05. Effect sizes in terms of direction (higher or lower FSH/AMH levels or AFCs) and magnitude (total differences in the mean hormone concentration or mean number of follicles from the overall regression fit) for the effect allele/genotype were compared for all variants tested. Interestingly, as shown in Table [IV](#DER391TB4){ref-type="table"} several variants associated with FSH or AMH were also associated with the number of antral follicles. The most significant variant, rs6543833, was associated with a decrease of 0.62 ± 0.34 IU/l FSH and an increase of 1.09 ± 0.32 antral follicles for the GG genotype (*P* = 9.25 × 10^−3^). Variant rs9875589 associated with AMH in African Americans, had the strongest association with follicle count; the effect allele, C, led to an increase of 14.02 ± 3.72 pM AMH and a corresponding increase of 4.88 ± 0.63 follicles (*P* = 1.84 × 10^−4^). Notably, in almost all cases the magnitudes and directions of effects were as expected, with variants associated with lower FSH levels correlated with higher follicle counts and variants associated with higher AMH levels correlated with higher follicle counts. Controlling for follicle number in the GWA of FSH/AMH did not affect the top associations. Further, there were both shared and independent associations between the hormonal markers and follicle number, indicating that both of these traits are independently associated with distinct genetic variants and are significant markers of ovarian reserve. Table IVAssociations between FSH- and AMH-related SNPs and AFC in African American and Caucasian women.SNP^a^RaceGeneAlleles^b^MAFFSH/AMH genotype effect (concentration)^c^AFC genotype effect (follicles)^d^*P*-value^e^rs6543833Afr Amer*MYADML***G**/C0.27−0.62 ± 0.34 (FSH)+1.09 ± 0.321.85 × 10^−3^ (9.25 × 10^−3^)\*rs12465811Afr Amer*MYADML***T**/G0.32−0.38 ± 0.24 (FSH)+0.94 ± 0.251.31 × 10^−3^ (6.55 × 10^−3^)\*rs9875589Afr Amer*TPRXL*A/**C**0.46+14.02 ± 3.72 (AMH)+4.88 ± 0.633.68 × 10^−5^ (1.84 × 10^−4^)\*rs12295403Afr Amer*TMEM86A***T**/G0.10+16.67 ± 5.11 (AMH)+5.17 ± 0.863.34 × 10^−3^ (1.67 × 10^−2^)\*rs11255291Afr Amer*ITIH2***T**/C0.25−1.34 ± 0.22 (FSH)+1.31 ± 0.360.211 (1)rs6488619Caucasian*GRIN2B*C/**T**0.25+1.16 ± 0.33 (FSH)+0.55 ± 0.0490.104 (0.416)rs10061804Caucasian*NPR3***T**/C0.28+2.05 ± 0.80 (FSH)+1.44 ± 0.300.310 (1)rs12213875Caucasian*JARID2***A**/G0.37+13.82 ± 4.18 (AMH)+3.08 ± 0.520.0514 (0.206)rs9396503Caucasian*JARID2***T**/G0.37+14.92 ± 4.60 (AMH)+3.74 ± 0.660.0415 (0.166)[^15][^16][^17][^18][^19][^20]

Phenotypes and covariates of ovarian reserve {#s3b}
--------------------------------------------

Serum levels of various circulating hormones potentially related to ovarian function and OVA were measured as shown in Table [I](#DER391TB1){ref-type="table"}. The means and ranges of hormone levels were within the spectrum of normal variation. There were significant differences between the hormone profiles of the two racial groups, with pronounced differences in AMH (*P* = 0.00074), LH (*P* = 2.28 × 10^−5^), inhibin B (*P* = 0.00049) and testosterone (*P* = 0.00041). All of these hormones were significantly lower in the African American women. The associations between environmental variables including smoking and OCP use, and ovarian reserve markers were also analyzed. Among the Caucasian population, 45.5% were either current or previous smokers (14.6 current and 30.9% previous smokers) with an overall average of 9.6 ± 0.6 years of smoking and a range of 1--25 years. Fewer African Americans were current or previous smokers with only 23.3% being current (11.4%) or previous (11.9%) smokers, with an overall average of 9.8 ± 1.2 years of smoking and a range of 1--27 years. There was no significant difference between the mean AFCs of women that were current or previous smokers versus that of non-smokers in the Caucasian cohort (*P* = 0.36) nor in the African American cohort (*P* = 0.34). In the Caucasian population, when controlling for age there was no correlation between the total pack-years of smoking and follicle number (*R*^2^ = −0.057, *P*\> 0.05). However, there was a trend for decreased follicle numbers among the smoking versus non-smoking African American women (14.3 ± 1.4 versus 16.0 ± 0.9, respectively). Although, owing to the small number of African American smokers further comparisons were not feasible.

As shown in Fig. [5](#DER391F5){ref-type="fig"}, the circulating serum levels of several reproductive and sex steroid hormones were significantly different between smoking and non-smoking Caucasian women. Testosterone levels were 56 ± 1.6 versus 50.3 ± 1.2 ng/dl (*P* = 0.0035), AMH levels were 33.5 ± 2.4 versus 27.4 ± 1.7 pM (*P* = 0.038) and E~1~ levels were 65.2 ± 2.8 versus 58.8 ± 1.7 pg/ml (*P* = 0.043), among smoking and non-smoking women, respectively (Fig. [5](#DER391F5){ref-type="fig"}G). The regression fit of these and other hormones with female age was also significantly different between smoking and non-smoking women, with the most pronounced differences in E~2~ and testosterone levels (*P* = 0.0045 and 0.0053, respectively; Fig. [5](#DER391F5){ref-type="fig"}E and F). The regression of AFC versus age was also significantly different between smoking and non-smoking women, with a greater extrapolated rate of follicle decline among smoking women (*P* = 0.039; Fig. [5](#DER391F5){ref-type="fig"}A). Figure 5The association between smoking or oral contraceptive use and several reproductive hormones and follicle counts. Shown are serum hormone levels or AFCs versus age for women that were current or previous smokers (red points) or non-smokers (black points) (**A--F**). The data for all women were fit with a linear regression (gray line) and the regressions for smoking (red line) and non-smoking (black line) women were compared. *P*-values indicate a significant change in slope, intercept or both slope and intercept, associated with smoking. There were significant differences in serum levels of estrone (E~1~), estradiol (E~2~) and testosterone (T), and AFC between smoking and non-smoking women (*P*\< 0.05). Also shown are mean serum levels of testosterone, E~1~ and AMH in smoking (closed bars) and non-smoking (open bars) women (**G**) and mean AFCs in oral contraceptive-using (open bars) and non-using (closed bars) African American and Caucasian women (**H**) (\**P*\< 0.05).

Seventy-nine percent of the Caucasian women and 72% of the African American women had previously used OCPs. Total months of use were 63.0 ± 4.2 (range = 1--216 months) in the Caucasian population and 56.0 ± 5.4 (range = 1--264 months) in the African American population. In the Caucasian women, there were no statistically significant differences between the mean serum hormone levels or AFCs of women who previously took OCPs versus those who did not (*P* \> 0.05). There was also no dose--response or association between the total number of months of OCP use and the total number of follicles (*R*^2^ = 0.014 and 1 × 10^−6^ in Caucasians and African Americans, respectively). In contrast, in the African American population there was a significant increase in the number of follicles in women who had never taken OCPs (*P* = 0.0046; Fig. [5](#DER391F5){ref-type="fig"}H). In both ethnic groups, there were trends for increased follicle numbers in women who had never taken OCPs compared with those who had (Caucasians: 17.2 ± 1.3 versus 14.8 ± 0.6, respectively, *P* = 0.058; African Americans: 18.9 ± 1.6 versus 14.3 ± 0.8, *P* = 0.0046; Fig. [5](#DER391F5){ref-type="fig"}H). There were similar trends with several reproductive hormones and AFC regressed on age, between previous OCP-users and non-OCP-users ([Supplementary data, Fig. S5](http://humrep.oxfordjournals.org/lookup/suppl/doi:10.1093/humrep/der391/-/DC1)). Despite the effects of smoking and OCP use on ovarian reserve phenotypes, adjusting for them in linear regression analyses did not affect the genetic associations. This indicates that the effect of each variant likely occurs directly on ovarian reserve/hormone levels, rather than through one of these covariates.

Discussion {#s4}
==========

Genetic variants associated with FSH and AMH {#s4a}
--------------------------------------------

As FSH and AMH are two established clinical markers of ovarian reserve and are closely associated with the number of antral follicles within the ovaries, we aimed to determine whether they might be associated with underlying genetic loci. Identification of these loci could provide markers and long-range predictors of poor ovarian reserve and infertility. Here, we used a genome-wide approach to analyze genetic variants associated with these reproductive hormones, as surrogate measures of ovarian reserve in a multi-ethnic fertile population of women. We identified 1 SNP, rs6543833, approaching genome-wide significance at *P* = 8.07 × 10^−8^ and several nominal SNPs associated with FSH levels in African American and Caucasian women, respectively, whereas, only nominally significant variants were associated with AMH levels. In validation studies, the top hit associated with FSH was significant in the other ethnic cohort (Caucasians). Additionally, there were nine adjacent SNPs in the nearby upstream region with significantly low *P*-values, and all were within or near the *MYADML* gene. We also found that several top hits associated with FSH or AMH were also significantly associated with follicle number, with similar magnitudes and directions of effects. These results provide validation of the association and evidence for underlying genetic associations between these three phenotypes, as well as their ability to serve as independent but also overlapping ovarian reserve markers. Moreover, several variants associated with AMH or FSH (this study), and follicle count (unpublished data), localized to the same genomic regions of 12p13.1--13.2 and 13q12.13, which may be a hot spot for causative alleles linked with ovarian reserve.

None of the variants were within or close to known ovarian genes and therefore identify excellent candidate genes for further investigations. While these findings are interesting and the largest study to date on genetic markers of FSH and AMH, future meta-analyses and additional validation in independent studies are needed. To our knowledge, this is the only study to genotype and examine ovarian reserve hormones in a fertile population of women. All previous cohort studies that have analyzed some aspect of ovarian reserve have utilized either post-menopausal women (over age 45 years) or women recruited through infertility/reproductive clinics and are therefore not reproductively 'normal' populations. This work is the first to analyze a cohort of women (non-menopausal) of reproductive age recruited from the general population and not seeking infertility treatments. This study is also the first to examine these reproductive traits in women of African as well as European ancestry, and may help to provide a baseline and foundation for future study of these ethnic groups.

As indicated by our previous work in a larger population of 245 Caucasian women, and validated here in both Caucasians and African Americans, of all hormonal, anthropometric and environmental variables, AMH and FSH were most closely associated with female age and follicle number. AMH paralleled the pattern observed between follicle number and age both *in vivo* and in histologic ovarian specimens ([@DER391C21]), while FSH was inversely related. Consistent with the role of AMH, we found that in Caucasian and African American women AMH and follicle number were closely related and both declined with female age. Interestingly, AMH levels were more variable among African American women compared with Caucasian women, and showed a weaker correlation with age. As predicted, FSH levels increased with both female age and decreasing follicle number in both ethnic groups, and surprisingly, were also more variable and less strongly correlated with age among African American than Caucasian women. It is interesting to note that none of the subjects had polycystic ovary syndrome or other reproductive disorders, which could be associated with elevated AMH or FSH levels. All women also had regular cycles and no hyperandrogenemia. Therefore, the greater variability cannot be explained by ovarian or other hormonal disorders. To our knowledge there is no other study with which to compare these results and no other study to assess these hormones in normal fertile women of African and European ancestry.

Several hormones, including FSH, AMH, E~2~ and inhibin B, among others, have been correlated with ovarian response to controlled ovarian stimulation or pregnancy outcomes in IVF cycles ([@DER391C15]; [@DER391C50]; [@DER391C49]). Studies have reported that AMH may be the best marker of ovarian reserve as it can be measured throughout the menstrual cycle and is more closely associated with the number of oocytes retrieved and reproductive outcomes in IVF ([@DER391C14]; [@DER391C50]; [@DER391C49]). AMH also has a reported lower variability within and between cycles in the same women ([@DER391C45]). Previous work has also identified a few variants in the genes encoding the receptors for AMH and FSH, AMHR2 ([@DER391C28]) and FSHR ([@DER391C20]; [@DER391C32]), and found correlations with various reproductive parameters including age at menopause, or FSH sensitivity and menstrual cycle length, respectively. Interestingly, a recent large-scale candidate gene association study found that the group of genes involved with steroid hormone metabolism and biosynthesis pathways including FSHB, was significantly associated with age of menopause ([@DER391C24]). This indicates that several reproductive (i.e. FSH) and sex steroid hormones may share underlying genetic associations that are linked with the reproductive lifespan. However, many of these studies relied on comparisons of hormone profiles and their ability to predict reproductive outcomes in the context of small populations of infertile or subfertile (or post-menopausal) women. Thus, we now identify genetic variants associated with markers of ovarian reserve in a large community-based population.

None of the genes associated with the identified variants have demonstrated roles in ovarian biology and are therefore interesting candidate genes. As FSH and AMH are related to ovarian function and reflective of ovarian reserve, the genes and variants associated with them might have roles in the brain-pituitary-ovary axis and be expressed within the ovary or brain---and some of them are. The two top variants, as well as other nearby variants associated with FSH are located upstream or within the *MYADML* gene at 2p22.3. *MYADML* has almost exclusive expression in the human testis and limited expression in the brain ([www.ncbi.nlm.nih.gov/unigene](www.ncbi.nlm.nih.gov/unigene)). However, the role of this gene in ovarian biology is unknown. The *GRIN2B* gene containing the top SNP at 12p13.1 associated with FSH in Caucasian women, encodes one subunit of the ionotropic NMDA glutamate receptor, which is involved in learning and memory and expressed within the brain and testis. Genetic association studies have implicated this gene in several neurological diseases ([@DER391C2]), however studies of this receptor in ovarian function are lacking. The two variants marginally associated with AMH in Caucasian women are located upstream of the *JARID2* gene at 6p23. *JARID2* is an ortholog of the mouse jumonji gene, which encodes a DNA-binding nuclear protein and regulator of histone methyltransferases that is essential for embryogenesis and differentiation. JARID2 negatively regulates cell growth and proliferation and is ubiquitously expressed, with expression in both human and mouse oocytes and ovary, and human embryonic stem cells (Ovarian Kaleidoscope: <http://ovary.stanford.edu/>) ([@DER391C4]). Therefore, JARID2 could play a role in germ cell and/or somatic cell growth within the developing ovary.

Interestingly, several variants associated with FSH or AMH were also associated with AFC and variants associated with all three ovarian reserve markers localized to some of the same genomic regions. A variant associated with AMH (rs17084228) and a variant associated with AFC, were located within the same 30-kb genomic region of 13q12.13, where the nearest genes are *GPR12* and *WASF3*. Both genes are predominantly expressed in the brain, with *WASF3* also highly expressed in the ovary. One SNP associated with FSH (rs6488619), and two other SNPs associated with AFC, were also located in a similar genomic region at 12p13.1 and 12p13.2, respectively. Therefore, these genomic regions on chromosomes 12 and 13, which also comprised long stretches of associated SNPs in LD, may be hot spots for causative alleles or genes associated with ovarian reserve. Further, as all of these ovarian reserve markers had both distinct and shared genetic loci, this emphasizes the multi-factorial and polygenic nature of ovarian reserve and female fertility. Future functional studies may examine the expression of these genes in human ovarian tissue and female germ cells, altered gene expression in ovarian tissue from women with different genotypes, and genetic over-expression and silencing studies in ovarian and stem cell lines. This work will help to elucidate the expression patterns and functional roles of these candidate genes in human ovarian biology.

Environmental factors associated with ovarian reserve {#s4b}
-----------------------------------------------------

Environmental factors can affect human reproductive traits. We discovered modest effects of smoking and OCP use on clinical markers of ovarian reserve, with alterations in several reproductive and sex steroid hormones, as well as follicle numbers. Smoking has adverse effects on fertility and pregnancy. There is continuing debate about the relationship between cigarette smoke and ovarian failure. Studies have reported an association between smoking and an earlier age at natural menopause, with women who smoke entering menopause 1--2 years earlier than comparable non-smokers ([@DER391C44]; [@DER391C5]; [@DER391C46]; [@DER391C9]; [@DER391C18]). Former smokers also reportedly have a slightly earlier age of menopause than non-smokers ([@DER391C48]; [@DER391C9]) and women prenatally exposed to maternal cigarette smoke may enter menopause sooner ([@DER391C43]). Limited studies on special patient/infertility populations have suggested that smoking is not associated with AFC or AMH levels ([@DER391C29]; [@DER391C36]) but is associated with elevated FSH levels ([@DER391C29]).

It is plausible that tobacco toxins have detrimental effects on the follicular pool and increase rates of follicular atrophy and atresia, leading to lower AFCs, alterations in ovarian reserve hormones, and ultimately, reduced fertility and an earlier menopause. We found that smoking was associated with increased serum levels of testosterone, E~1~, E~2~, AMH and a trend for increased FSH levels. This underscores the potential effects of smoking on the ovarian reserve and suggests that smoking may alter steroidogenesis, OVA and/or the hypothalamic-pituitary-ovarian axis. Indeed, previous work has found that levels of sex steroid hormones, such as testosterone, are significantly elevated in smokers ([@DER391C13]; [@DER391C10]), while other studies have reported alterations in sex steroids including lower concentrations of E~1~, E~2~ and estriol ([@DER391C42]).

Other effects of tobacco toxins include increased rates of apoptosis and necrosis in various tissues of the body, as well as increased apoptosis in primordial germ cells differentiated from human stem cells *in vitro* ([@DER391C27]). These effects might also manifest as increased rates of follicular apoptosis or dysfunction within the ovaries. Indeed, polycyclic aromatic hydrocarbons in cigarette smoke are toxic to ovarian follicles in both animal models ([@DER391C16]) and humans ([@DER391C33]). We found that neither previous nor current smoking was associated with overall lower follicle counts. However, smoking was associated with an increased extrapolated rate of follicular decline in Caucasian women (*P* = 0.039). There was no dose-response between the pack-years of smoking and follicle number (*P*\> 0.05). Our findings are consistent with the work of Gold and co-workers, one of the largest, most comprehensive studies on menopause ([@DER391C18]). In 14 620 middle-aged women of the Study of Women\'s Health Across the Nation, smoking was associated with an earlier age of menopause (0.3--1.2 years earlier) but there was no dose--response effect of the amount of cigarettes smoked per day on menopausal age. Similarly, we found no dose--response of smoking but smoking was positively correlated with an increased rate of follicular decline. There was also a positive correlation between female age and number of years of smoking, with older women on average having smoked for a greater number of years. Any effects of smoking on the follicle pool therefore, might be most evident in mid-life.

A slightly later age of menopause has been reported in women that previously used OCPs ([@DER391C46] [@DER391C46]; [@DER391C18]), while other studies have reported no association ([@DER391C5]; [@DER391C22]). It has been hypothesized that OCP use delays menopause by the hormonal actions of suppressing follicular recruitment and ovulation, thereby leading to increased numbers of follicles. In contrast, we found that OCP use did not increase follicle number. Instead, women who had taken OCPs had similar or slightly lower follicle numbers compared with women who had never taken OCPs (*P* = 0.058 in Caucasians and *P* = 0.0046 in African Americans). Similar to previous work on menopause ([@DER391C18]), we found no relation between duration of prior OCP use and follicle number or serum hormone levels. These results suggest that OCP use is not associated with increased follicle number or alterations in ovarian reserve hormones. It remains speculative that oral contraceptives may actually have some subtle inhibitory effects on follicle numbers or ovarian reserve in women of reproductive age. However, as we are limited by sample size, longitudinal studies analyzing these lifestyle factors in larger cohorts of women could provide further insight on the biological effects of these exposures on the ovarian reserve. It is likely that complex genetic and environmental influences affect follicular atresia, as well as the brain-pituitary-ovary axis and its regulation of gonadotrophins and sex steroid hormones.

Conclusion {#s5}
==========

This is the first genome-wide study to evaluate genetic associations with hormone markers of ovarian reserve. We found several differences between the ovarian reserve phenotypes of Caucasian and African American women---differences in AMH levels and subtle differences in the associations between hormonal markers with age and follicle number. Smoking and OCP use were associated with alterations in reproductive hormone profiles and/or follicle number in both ethnic groups. We identified one variant of marginal genome-wide significance and several nominally-significant variants associated with FSH levels in African American women, as well as nominal variants associated with FSH and AMH levels in both ethnic groups. These variants were validated in the Caucasian cohort. Several of the variants were also significantly associated with follicle number. Interestingly, none of the associated genes have previously demonstrated roles in ovarian function and now represent a group of candidate genes for further investigation. Future studies including multi-site meta-analyses on additional larger cohorts of women and replication in independent studies are needed. Fine mapping or sequencing and functional *in vitro* gene expression and gain- and loss-of-function studies on the identified candidate genes might reveal any effects of the genetic variants and the putative functions of these genes. Longitudinal studies are also needed to explore the effect of these variants and genes on the decline in ovarian reserve with age.

A better understanding of the genes and environmental factors that impact ovarian reserve may provide greater insight on the process of reproductive aging, the genetic requirements of human fertility and risk for development of disease. It is hoped that this work may help form a foundation for genetically identifying women at risk for early ovarian failure, fertility defects and hence associated reproductive and somatic diseases.
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[^1]: Values are shown as mean ± SEM or percentage of the cohort.

[^2]: AMH, anti-Mullerian hormone; OCP, oral contraceptive pill.

[^3]: ^a^Parentheses denote AFC values (mean ± SEM).

[^4]: \*Significant differences between Caucasian and African American women (*P*\< 0.001).

[^5]: Genes: *MYADML*, myeloid-associated differentiation marker line; *ITIH2*, inter-alpha (globulin) inhibitor H2; *GRIN2B*, glutamate receptor, ionotropic, N-methyl D-aspartate 2B; *NPR3*, natriuretic peptide receptor C/guanylate cyclase C; SNP, single nucleotide polymorphism; Chr, chromosome; MAF, minor allele frequency.

[^6]: ^a^Alleles are shown as minor/major allele.

[^7]: ^b^The difference in mean (±SEM) serum FSH levels (IU/l) for a given genotype. 'A' denotes the minor allele and 'B' denotes the major allele.

[^8]: ^c^*P*-values are based on the Fisher\'s exact test for SNP association with FSH.

[^9]: ^d^*P*-values corrected at the chromosome-level (and genome-wide level) by permutation testing and Bonferroni correction.

[^10]: Genes: *TPRXL*, tetra-peptide repeat homeobox-like; *TMEM86A*, transmembrane protein 86A; *JARID2*, jumonji, *AT* rich interactive domain 2.

[^11]: ^a^Alleles are shown as minor/major allele.

[^12]: ^b^The difference in mean (±SEM) serum AMH levels (pM) for a given genotype. 'A' denotes the minor allele and 'B' denotes the major allele.

[^13]: ^c^*P*-values are based on the Fisher\'s exact test for SNP association with AMH.

[^14]: ^d^*P*-values corrected at the chromosome-level (and genome-wide level) by permutation testing and Bonferroni correction.

[^15]: *P* \< 0.05 for four out of five FSH/AMH-associated SNPs also associated with AFC, compared with 0.34 (\<1) expected by chance.

[^16]: ^a^SNPs at each locus are those associated with serum FSH or AMH levels, rather than those with the strongest signal for follicle number.

[^17]: ^b^Alleles are shown as minor/major allele; bold indicates the effect allele.

[^18]: ^c^The difference in mean (±SEM) serum FSH levels (IU/l) or AMH levels (pM) for a given genotype.

[^19]: ^d^The difference in mean (±SEM) number of follicles for the corresponding genotype calculated from the regression analysis.

[^20]: ^e^*P*-values are based on the Fisher\'s exact test for SNP association with the hormone; parentheses denote corrected *P*-values; \**P* \< 0.05.
